| Literature DB >> 35255911 |
Aibibai Yiming1, Muhetaer Wubulikasimu1, Nuermaimaiti Yusuying2.
Abstract
BACKGROUND: This study aimed to identify the factors underlying the metastasis of breast cancer and sentinel lymph nodes and to screen and analyze the risk factors of sentinel lymph node metastasis to provide a reference and basis for clinical work.Entities:
Keywords: Breast cancer; Factors; Molecular pathology; Sentinel lymph node
Mesh:
Substances:
Year: 2022 PMID: 35255911 PMCID: PMC8902784 DOI: 10.1186/s12957-022-02531-3
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Univariate logistic regression analysis of general data of the two groups of patients
| General information | Classification | Lymph node metastasis group ( | Non-lymph node metastasis group ( | |||
|---|---|---|---|---|---|---|
| Age | 62 (47–78) | 53 (45–72) | 3.74 | 1.24 (1.07~1.41) | 0.04 | |
| Tumor diameter (cm) | 8 (4–8) | 4 (2–8) | 5.77 | 1.45 (1.26~1.63) | 0.02 | |
| Tumor number (%) | Single | 40 (81.63%) | 43 (86%) | 0.13 | 0.93 (0.41~1.30) | 0.94 |
| Multiple | 9 (18.37%) | 7 (14%) | ||||
| Tumor location (%) | Left | 28 (57.14%) | 26 (52%) | 0.24 | 0.98 (0.93~1.07) | 0.77 |
| Right | 21 (42.86%) | 24 (48%) | ||||
| Tumor quadrant (%) | Outside and up | 26 (55.06%) | 25 (50%) | 0.29 | 0.91 (0.52~1.24) | 0.77 |
| Outside and down | 7 (14.29%) | 8 (16%) | ||||
| Inside and up | 13 (26.53%) | 15 (30%) | ||||
| Inside and down | 2 (4.08%) | 1 (2%) | ||||
| Center | 1 (2.04%) | 1 (2%) |
Univariate logistic regression analysis of color ultrasonography characteristics
| Characteristic | Classification | Lymph node metastasis group ( | Non-lymph node metastasis group ( | |||
|---|---|---|---|---|---|---|
| Tumor margin (%) | Regular | 4 (8.16%) | 8 (16%) | 1.37 | 1.04 (0.77~1.31) | 0.13 |
| Irregular | 45 (91.84%) | 42 (84%) | ||||
| Blood flow signal (c%) | No | 10 (20.41%) | 12 (24%) | 0.04 | 0.93 (0.81~1.07) | 0.93 |
| Yes | 39 (79.59%) | 38 (76%) | ||||
| Posterior echo attenuation (%) | No | 20 (40.82%) | 24 (48%) | 0.94 | 0.90 (0.55~1.10) | 0.13 |
| Yes | 29 (59.18%) | 26 (52%) | ||||
| BI-RADS grade (%) | < 4 | 3 (6.12%) | 6 (12%) | 7.22 | 1.42 (1.23~1.69) | 0.00 |
| 4a | 4 (8.16%) | 9 (18%) | ||||
| 4b | 10 (20.41%) | 15 (30%) | ||||
| 4c | 12 (24.49%) | 13 (26%) | ||||
| 5 | 20 (40.82%) | 7 (14%) |
Univariate logical regression analysis of molybdenum target characteristics
| Characteristic | Classification | Lymph node metastasis group ( | Non-lymph node metastasis group ( | |||
|---|---|---|---|---|---|---|
| Tumor margin (%) | Regular | 7 (14.29%) | 14 (28%) | 1.81 | 1.09 (0.83~1.21) | 0.07 |
| Irregular | 42 (85.71%) | 36 (72%) | ||||
| Calcification (c%) | Without | 26 (53.06%) | 23 (46%) | 0.94 | 1.01 (0.71~1.19) | 0.20 |
| With | 23 (46.94%) | 27 (54%) | ||||
| BI-RADS grade (%) | < 4 | 6 (12.24%) | 10 (20%) | 6.23 | 1.32 (1.14~1.57) | 0.02 |
| 4a | 9 (18.37%) | 12 (24%) | ||||
| 4b | 14 (28.57%) | 15 (30%) | ||||
| 4c | 11 (22.45%) | 8 (16%) | ||||
| 5 | 9 (18.37%) | 5 (10%) |
Fig. 1The evaluation criteria of ER, PR, and HER in the groups
Univariate logistic regression was used to analyze the routine pathological characteristics of the two groups
| Characteristic | Classification | Lymph node metastasis group ( | Non-lymph node metastasis group ( | |||
|---|---|---|---|---|---|---|
| Histological level (%) | I | 7 (14.28%) | 10 (20%) | 0.75 | 0.90 (0.72~1.09) | 0.27 |
| II | 32 (65.31%) | 30 (60%) | ||||
| III | 10 (20.41%) | 10 (20%) | ||||
| Pathological type (%) | DCIS | 3 (6.12%) | 11 (22%) | 4.04 | 1.21 (1.06~1.40) | 0.04 |
| IDC | 46 (93.88%) | 39 (78%) | ||||
| Molecular type (%) | Luminal A | 11 (22.45%) | 9 (18%) | 2.06 | 0.93 (0.41~1.30) | 0.07 |
| Luminal B | 14 (28.57%) | 10 (20%) | ||||
| HER2 overexpress | 16 (32.65%) | 21 (42%) | ||||
| Tri-negative | 8 (16.33%) | 10 (20%) |
Fig. 2Special immunohistochemical evaluation criteria
Univariate logical regression analysis of the special immunohistochemical characteristics
| Characteristic | Lymph node metastasis group ( | Non-lymph node metastasis group ( | |||
|---|---|---|---|---|---|
| CK5/6 (grade) | 10 (9–12) | 3 (1–6) | 4.14 | 1.33 (1.10~1.52) | 0.01 |
| E-cadherin (grade) | 8 (6–11) | 7 (5–11) | 0.75 | 1.01 (0.76~1.23) | 0.29 |
| MDR-1 (grade) | 3 (1–6) | 3 (1–5) | 0.22 | 0.94 (0.68~1.23) | 0.89 |
| EGFR (grade) | 10 (8–12) | 7 (4–10) | 3.84 | 1.29 (1.12~1.48) | 0.04 |
| CK19 (grade) | 9 (6–12) | 3 (1–5) | 4.07 | 1.31 (1.17~1.56) | 0.03 |
Univariate logistic regression analysis of gene mutations
| Characteristic | Classification | Lymph node metastasis group ( | Non-lymph node metastasis group ( | |||
|---|---|---|---|---|---|---|
| TP53 (%) | Without | 7 (14.29%) | 1 (2%) | 3.88 | 1.23 (1.04~1.39) | 0.04 |
| With | 42 (85.71%) | 49 (98%) | ||||
| BRAC1/2 (%) | Without | 6 (12.24%) | 0 (0%) | 3.80 | 1.21 (1.01~1.33) | 0.04 |
| With | 43 (87.76%) | 50 (100%) | ||||
| BRAF (%) | Without | 0 (0%) | 2 (4%) | 0.17 | 0.94 (0.82~1.04) | 0.90 |
| With | 49 (100%) | 48 (96%) | ||||
| ATM (%) | Without | 0 (0%) | 0 (0%) | 0.04 | 0.92 (0.90~0.95) | 0.98 |
| With | 49 (100%) | 50 (100%) | ||||
| PALB2 (%) | Without | 1 (2.04%) | 0 (0%) | 0.14 | 0.79 (0.68~0.89) | 0.97 |
| With | 48 (97.96%) | 50 (100%) |
Logical regression analysis of multiple factors
| Factors | 95% | |||||
|---|---|---|---|---|---|---|
| Age | 0.65 | 0.43 | 8.60 | 0.02 | 3.52 | 2.78~6.04 |
| Tumor diameter | 0.51 | 0.60 | 8.10 | 0.00 | 4.04 | 3.27~6.51 |
| BI-RADS grade | 0.73 | 0.28 | 7.04 | 0.03 | 3.10 | 2.33~5.28 |
| Pathological type | 0.53 | 0.63 | 6.94 | 0.04 | 3.07 | 2.50~4.92 |
| CK5/6 | 0.60 | 0.46 | 8.01 | 0.02 | 3.37 | 2.99~5.78 |
| EGFR | 0.58 | 0.59 | 7.33 | 0.03 | 3.24 | 2.40~6.13 |
| CK19 | 0.75 | 0.23 | 7.88 | 0.03 | 3.18 | 2.46~5.90 |
| TP53 | 0.56 | 0.59 | 7.10 | 0.03 | 3.14 | 2.28~5.04 |
| BRAC1/2 | 0.51 | 0.64 | 6.99 | 0.04 | 3.04 | 2.34~4.20 |
Fig. 3ROC curve of independent risk factors for sentinel lymph node metastasis in breast cancer. A Age, B tumor diameter, C BI-RADS grades, D pathological type, E CK5/6, F EGFR, G CK19, H TP53, and I BRAC1/2